

**South East London Area Prescribing Committee
Formulary recommendation**

Reference	026
Intervention:	Dapoxetine hydrochloride (Priligy®) 30 mg and 60 mg film-coated tablets for premature ejaculation (Dapoxetine hydrochloride is a selective serotonin reuptake inhibitor (SSRI) with a short duration of action)
Date of Decision	March 2015
Date of Issue:	March 2015
Recommendation:	Grey – not recommended for prescribing in South East London
Further Information	The South East London APC is unable to support the use of dapoxetine for treating premature ejaculation because local specialists did not complete the required formulary submission. Dapoxetine will be grey listed until a submission is received from local clinicians in South East London for it to be considered for formulary inclusion.
Shared Care/Transfer of care document required:	N/A
Cost Impact for agreed patient group	N/A
Usage Monitoring & Impact Assessment	Trusts – monitor non-formulary requests CCGs – monitor impact data
Evidence reviewed	N/A

NOTES:

- a) Area Prescribing Committee recommendations and minutes are available publicly on member CCG websites.
- b) This Area Prescribing Committee recommendation has been made on the cost effectiveness, patient outcome and safety data available at the time. The recommendation will be subject to review if a submission is received or new NICE guidelines or technology appraisals are issued.
- c) Not to be used for commercial or marketing purposes. Strictly for use within the NHS